Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: PR Newswire
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswire
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.MarketBeat
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmPR Newswire
- Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]Yahoo! Finance
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmGlobeNewswire
RLMD
Earnings
- 8/7/24 - Beat
RLMD
Sec Filings
- 10/23/24 - Form 4
- 9/13/24 - Form EFFECT
- 9/11/24 - Form 4
- RLMD's page on the SEC website